NCT04626635: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 1 year, 8 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04626635 |
|---|---|
| Title | A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 21, 2020 |
| Completion date | Aug. 19, 2026 |
| Required reporting date | Aug. 19, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |